vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与RANGE RESOURCES CORP（RRC）财务数据对比。点击上方公司名可切换其他公司
RANGE RESOURCES CORP的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.9倍（$786.9M vs $406.6M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs 22.8%，领先37.7%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 18.0%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 14.6%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Range Resources Corporation是一家总部位于美国得克萨斯州沃斯堡的天然气勘探开采企业，核心运营区域为马塞勒斯页岩地层，是该地区拥有土地面积最大的运营商，专注于天然气资源的勘探、开发与生产业务，在北美油气开发领域具备深厚的行业积累。
BCRX vs RRC — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $786.9M |
| 净利润 | $245.8M | $179.1M |
| 毛利率 | 97.7% | 94.5% |
| 营业利润率 | 64.0% | — |
| 净利率 | 60.5% | 22.8% |
| 营收同比 | 209.1% | 18.0% |
| 净利润同比 | 1017.5% | 88.8% |
| 每股收益（稀释后） | $1.13 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $406.6M | $786.9M | ||
| Q3 25 | $159.4M | $655.3M | ||
| Q2 25 | $163.4M | $699.6M | ||
| Q1 25 | $145.5M | $846.3M | ||
| Q4 24 | $131.5M | $667.0M | ||
| Q3 24 | $117.1M | $567.9M | ||
| Q2 24 | $109.3M | $513.2M | ||
| Q1 24 | $92.8M | $598.8M |
| Q4 25 | $245.8M | $179.1M | ||
| Q3 25 | $12.9M | $144.3M | ||
| Q2 25 | $5.1M | $237.6M | ||
| Q1 25 | $32.0K | $97.1M | ||
| Q4 24 | $-26.8M | $94.8M | ||
| Q3 24 | $-14.0M | $50.7M | ||
| Q2 24 | $-12.7M | $28.7M | ||
| Q1 24 | $-35.4M | $92.1M |
| Q4 25 | 97.7% | 94.5% | ||
| Q3 25 | 98.6% | 92.5% | ||
| Q2 25 | 98.3% | 95.0% | ||
| Q1 25 | 96.9% | 93.1% | ||
| Q4 24 | 95.4% | 93.7% | ||
| Q3 24 | 97.3% | 94.3% | ||
| Q2 24 | 98.4% | 93.4% | ||
| Q1 24 | 98.6% | 94.7% |
| Q4 25 | 64.0% | — | ||
| Q3 25 | 18.6% | — | ||
| Q2 25 | 18.2% | — | ||
| Q1 25 | 14.6% | — | ||
| Q4 24 | -3.4% | — | ||
| Q3 24 | 6.6% | — | ||
| Q2 24 | 8.0% | — | ||
| Q1 24 | -15.6% | — |
| Q4 25 | 60.5% | 22.8% | ||
| Q3 25 | 8.1% | 22.0% | ||
| Q2 25 | 3.1% | 34.0% | ||
| Q1 25 | 0.0% | 11.5% | ||
| Q4 24 | -20.4% | 14.2% | ||
| Q3 24 | -12.0% | 8.9% | ||
| Q2 24 | -11.6% | 5.6% | ||
| Q1 24 | -38.1% | 15.4% |
| Q4 25 | $1.13 | $0.75 | ||
| Q3 25 | $0.06 | $0.60 | ||
| Q2 25 | $0.02 | $0.99 | ||
| Q1 25 | $0.00 | $0.40 | ||
| Q4 24 | $-0.13 | $0.38 | ||
| Q3 24 | $-0.07 | $0.21 | ||
| Q2 24 | $-0.06 | $0.12 | ||
| Q1 24 | $-0.17 | $0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $204.0K |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $-119.2M | $4.3B |
| 总资产 | $514.2M | $7.4B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
| Q4 25 | $274.7M | $204.0K | ||
| Q3 25 | $212.9M | $175.0K | ||
| Q2 25 | $260.0M | $134.0K | ||
| Q1 25 | $295.1M | $344.6M | ||
| Q4 24 | $320.9M | $304.5M | ||
| Q3 24 | $96.8M | $277.4M | ||
| Q2 24 | $78.4M | $251.1M | ||
| Q1 24 | $84.3M | $343.1M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.8B |
| Q4 25 | $-119.2M | $4.3B | ||
| Q3 25 | $-387.9M | $4.2B | ||
| Q2 25 | $-421.6M | $4.1B | ||
| Q1 25 | $-451.9M | $3.9B | ||
| Q4 24 | $-475.9M | $3.9B | ||
| Q3 24 | $-468.6M | $3.9B | ||
| Q2 24 | $-475.6M | $3.9B | ||
| Q1 24 | $-476.2M | $3.8B |
| Q4 25 | $514.2M | $7.4B | ||
| Q3 25 | $446.4M | $7.2B | ||
| Q2 25 | $457.2M | $7.1B | ||
| Q1 25 | $480.0M | $7.4B | ||
| Q4 24 | $490.4M | $7.3B | ||
| Q3 24 | $491.3M | $7.2B | ||
| Q2 24 | $472.4M | $7.3B | ||
| Q1 24 | $467.9M | $7.4B |
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.44× | ||
| Q1 24 | — | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $257.5M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | — |
| 自由现金流率自由现金流/营收 | 71.6% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | 1.19× | 1.44× |
| 过去12个月自由现金流最近4个季度 | $344.9M | — |
8季度趋势，按日历期对齐
| Q4 25 | $292.0M | $257.5M | ||
| Q3 25 | $41.6M | $247.5M | ||
| Q2 25 | $41.3M | $336.2M | ||
| Q1 25 | $-27.5M | $330.1M | ||
| Q4 24 | $-5.2M | $217.9M | ||
| Q3 24 | $8.2M | $245.9M | ||
| Q2 24 | $-1.4M | $148.8M | ||
| Q1 24 | $-53.7M | $331.9M |
| Q4 25 | $291.2M | — | ||
| Q3 25 | $40.3M | — | ||
| Q2 25 | $41.1M | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-53.9M | — |
| Q4 25 | 71.6% | — | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | -19.0% | — | ||
| Q4 24 | -4.5% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | -1.4% | — | ||
| Q1 24 | -58.1% | — |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 1.19× | 1.44× | ||
| Q3 25 | 3.23× | 1.72× | ||
| Q2 25 | 8.12× | 1.42× | ||
| Q1 25 | -859.91× | 3.40× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 4.85× | ||
| Q2 24 | — | 5.18× | ||
| Q1 24 | — | 3.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
暂无分部数据
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
